Skip to Content

Fluvirin Preservative-Free 2017-2018 (influenza virus vaccine, inactivated) Disease Interactions

There are 3 disease interactions with Fluvirin Preservative-Free 2017-2018 (influenza virus vaccine, inactivated):

Major

Influenza vaccine (Includes Fluvirin Preservative-Free 2017-2018) ↔ GBS

Severe Potential Hazard, Moderate plausibility. Applies to: Guillain-Barre Syndrome

The use of influenza vaccine has been associated with an elevated risk of Guillain-Barré syndrome (GBS). It is not recommended to administer this vaccine if GBS has occurred within 6 weeks following previous influenza vaccination. Care and close monitoring is recommended and consideration of the potential benefits and risks should be assessed.

Major

Vaccination (Includes Fluvirin Preservative-Free 2017-2018) ↔ infections

Severe Potential Hazard, High plausibility. Applies to: Fever, Infection - Bacterial/Fungal/Protozoal/Viral

Ideally, vaccination should occur when an individual is healthy, thus minimizing the risk of an adverse host reaction and/or vaccine failure. However, a current or recent infection does not necessarily preclude the use of vaccines, depending on the severity of the patient's symptoms and their etiology. Superficial infections and minor acute illnesses such as a mild upper respiratory infection with or without low-grade fever do not contraindicate immunization, particularly if prompt administration of a vaccine is deemed necessary or beneficial. In fact, when vaccines are administered during the course of a minor illness, the risk of adverse events is not increased, and serum antibody response is not often diminished. On the other hand, if fever or symptoms suggest a moderate or severe illness, it is usually appropriate to withhold vaccination until the patient has recovered. In addition to the potential risks already mentioned, evolving signs and symptoms of the illness can sometimes confound the diagnosis of a vaccine reaction if it develops. In the presence of any infection, the decision to administer or withhold/defer immunization should take into consideration the benefits versus the risks to an individual patient.

References

  1. "Product Information. Cholera vaccine (cholera vaccine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  2. "Product Information. Pneumovax 23 (pneumococcal vaccine, polyvalent)." Merck & Co, Inc, West Point, PA.
  3. "Product Information. YF-Vax (yellow fever vaccine)." sanofi pasteur, Swiftwater, PA.
  4. "Product Information. Typhim Vi (typhoid vaccine)." Connaught, Swiftwater, PA.
  5. "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.
  6. "Product Information. Varivax (varicella virus vaccine live)." Merck & Co, Inc, West Point, PA.
  7. "Product Information. Engerix-B (hepatitis B vaccine)." SmithKline Beecham, Philadelphia, PA.
  8. "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.
  9. "Product Information. Orimune (poliovirus vaccine, live, oral, trivalent)." Lederle Laboratories, Philadelphia, PA.
  10. "Product Information. Menomune-A/C/Y/W-135 (meningococcal polysaccharide vaccine)." Connaught, Swiftwater, PA.
  11. "Product Information. Mumpsvax (mumps virus vaccine (live).)." Merck & Co, Inc, West Point, PA.
  12. American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases. 24th" Grove Village, IL: American Academy of Pediatrics (1997):
  13. "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.
  14. "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.
  15. "Product Information. Plague Vaccine (plague vaccine)." Greer Laboratories Inc, Lenoir, NC.
View all 15 references
Moderate

Vaccines (inactivated)/toxoids (Includes Fluvirin Preservative-Free 2017-2018) ↔ immunodeficiency

Moderate Potential Hazard, High plausibility. Applies to: Immunodeficiency

The expected serum antibody responses may not be obtained when vaccines and/or toxoids are administered to patients with primary or acquired immunodeficiency, including those with severe combined immunodeficiency, hypogammaglobulinemia or agammaglobulinemia, HIV infection, altered immune states (due to diseases such as leukemia, lymphoma, or generalized malignancy), or immunosuppression due to drug or other treatments (e.g., corticosteroids, alkylating agents, antimetabolites, or radiation).

References

  1. "Product Information. Fluzone Influenza Vaccine (influenza virus vaccine)." Connaught, Swiftwater, PA.
  2. "Product Information. Omnihib (haemophilus b conjugate vaccine)." SmithKline Beecham, Philadelphia, PA.
  3. "Product Information. Tetanus Toxoid Adsorbed (tetanus toxoid)." Aventis Pasteur Inc, Swiftwater, PA.
  4. "Product Information. Typhim Vi (typhoid vaccine)." Connaught, Swiftwater, PA.
  5. American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases. 24th" Grove Village, IL: American Academy of Pediatrics (1997):
  6. "Product Information. Pneumovax 23 (pneumococcal vaccine, polyvalent)." Merck & Co, Inc, West Point, PA.
  7. "Product Information. Engerix-B (hepatitis B vaccine)." SmithKline Beecham, Philadelphia, PA.
  8. "Product Information. Plague Vaccine (plague vaccine)." Greer Laboratories Inc, Lenoir, NC.
  9. "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.
  10. "Product Information. Menomune-A/C/Y/W-135 (meningococcal polysaccharide vaccine)." Connaught, Swiftwater, PA.
View all 10 references

Fluvirin Preservative-Free 2017-2018 (influenza virus vaccine, inactivated) drug interactions

There are 219 drug interactions with Fluvirin Preservative-Free 2017-2018 (influenza virus vaccine, inactivated)

More about Fluvirin Preservative-Free 2017-2018 (influenza virus vaccine, inactivated)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide